Future Pulse Cardiology
Lp(a): a basic clinical approach with Dr. Steven Nissen Part 1 of 2
Feb 13, 2024
Dr. Steven Nissen, the Chief Academic Officer at the Cleveland Clinic and a leading expert in cardiology, joins Dr. Thomas Nero to discuss the critical role of lipoprotein(a) in cardiovascular disease. They emphasize the necessity of routine testing for Lp(a), particularly for those with family histories of heart disease. The conversation includes challenges in lowering Lp(a) levels, the limitations of current treatments, and insights into ongoing clinical trials for drugs like pellicarsin. Real patient scenarios highlight aggressive strategies for managing elevated LDL post-myocardial infarction.
11:00
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Routine screening for lipoprotein(a) is essential for early detection of cardiovascular risk, especially for those with a family history.
- Current research is exploring therapies to lower lipoprotein(a) levels, emphasizing individualized treatment approaches based on patient risk factors.
Deep dives
Understanding Lipoprotein(a) and Its Risks
Lipoprotein(a) is a type of cholesterol particle that significantly increases the risk of developing coronary artery disease, being more atherogenic than LDL cholesterol. Levels exceeding 70 milligrams per deciliter heighten the risk of cardiovascular disease, potentially doubling or tripling it. In particular, elevated levels of lipoprotein(a) contribute to both atherosclerosis and thrombosis, which are critical factors in heart disease. Therefore, it is crucial for individuals to know their lipoprotein(a) levels, especially if they have a family history of coronary heart disease.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
